Diabetes Mellitus has been growing at an exponential rate and World Health Organization (WHO) estimates that the diabetic population is likely to reach 366 million in 2030. The United States is expected to have an increase of 102 per cent in the diabetic epidemic in 2030 when compared to 2000. Likewise, Europe is likely to face a 43 per cent increase, Asia Pacific is expected to witness a 130 per cent increase and Africa and Middle East is likely to face a huge 162 per cent increase in diabetic population.
Diabetes is a chronic disease that arises when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin it produces. Insulin is a hormone synthesized in significant quantities in beta cells in the pancreas. Insulin enables cells to take in glucose from the blood and use it for energy.
Insulin Dependent Patients represent approximately 50% of the multi-billion dollar global diabetes market. This rapidly growing segment is Orgenesis’ technology focus and target market.
Diabetes - A Global Overview
- An estimated 285 million people, corresponding to 6.4 per cent of the world's adult population, are living with diabetes. The diabetic population is expected to explode to 438 million by 2030, corresponding to 7.8 per cent of the adult population.
- At present, the age group affected the most is between 40 and 59 years. By 2030, the 60-79 years age group is likely to be affected the most.
- India has the world's largest diabetes population (50.8 million).
- China has the second largest diabetes population (43.2 million).
- 70 per cent of the existing cases of diabetes are found in low- and middle-income countries.
- The prevalence varies from 10.2 per cent in the Western Pacific to 3.8 per cent in the African region.
The prevalence of diabetes has been increasing at an annual rate of 5 per cent and the trend is continuing. Analysis on the cause of diabetes reveals that obesity is the primary factor fuelling the incidence of diabetes. Obesity and diabetes are the two major problems currently faced by the medical community. Increase in obesity especially among younger people has led to the higher incidence of adult-onset or type-2 diabetes. Children are becoming obese due to lifestyle disorders and hence, this health problem is causing serious concern among the healthcare authorities globally.
Global Diabetes Epidemic (From 2000 to 2030 - in millions)
Diabetes Market Growth (2008 to 2015)
The global diabetes market is expected to reach $44.70 billion in 2015 with a compound annual growth rate (CAGR) of 7.5 per cent. The growth in the Asian market is estimated to be high fuelling the Rest-of-World market share to 15.9 per cent in 2015. Europe and Japan are expected to have a share of 31.3 and 9.5 per cent in 2015.
Please click on the countries to expand
In the United States about 24 million people are estimated to be affected with diabetes. Out of this 24 million approximately 23.0 per cent (5.7 million) still remain undiagnosed. About 1.6 million new cases were diagnosed in people aged 20 and over. In the United States, diabetes is the leading cause of blindness, kidney failure and amputations. People with diabetes have higher risk of death than those without diabetes.
Around $174.00 billion is spent towards direct and indirect costs due to diabetes. The direct medical costs add up to $116.00 billion. The U.S. market is the major geographical market holding more than 50 per cent of the revenues. However, the market is maturing, thereby forcing pharmaceutical participants to look for emerging areas in diabetes. Though the market is maturing the incidence of new diabetes cases is providing revenue generation opportunities for the companies.
The current European diabetes population is expected to be around 30 million.
Type-2 diabetes is highly prevalent in the European countries. This accounts for most of the diabetes treatment costs incurred by the governments. As type-2 diabetes is expected to increase, the expenditure to treat diabetes and its related complications are also expected to increase. It has been studied that the European Union incurred around Euros 29.00 billion towards diabetes treatment.
In a majority of the European countries, prevalence of obesity has increased by almost 10 to 50 per cent and as much as 60 per cent of the adult population is obese in some of the European countries. Obesity in children is estimated to be up to 30 per cent in some of the countries. Increasing obesity and aging population have increased the incidence of diabetes in Europe. Therefore, the healthcare expenditures due to diabetes have increased considerably.
The European diabetes market is dominated by Germany, followed by the United Kingdom. They constitute more than half of the total market. Germany is estimated to hold 33.5 per cent, while the United Kingdom has 21.0 per cent. The other countries such as France, Italy and Spain hold 14.5, 12.2 and 8.3 per cent, respectively. Scandinavian and Benelux countries constitute 5.0 and 5.5 per cent, respectively.
Estimated Total Diabetes Therapeutics Market Size (2009)
Source: Frost & Sullivan
Once a disease associated with western obesity, diabetes has become a global health predicament. The silent prevalence of diabetes is taking center stage as a threat to the Asian population.
There are many causes to the rise of diabetes within the Asian region, but the most common factors are aging populations, increased industrialization, poor eating habits, and often sedentary lifestyles. In 2010, approximately 135 million adults will be affected by diabetes in Asia, at a prevalence rate of 7%.
The two countries with the highest prevalence of diabetes are India and China, and it is estimated that by the year 2030, 7 of the 10 countries with the highest number of diabetics will be from Asia. Figure 1-1 gives a current snapshot of diabetes prevalence in a select group of Asian countries, comprising of China, India, South Korea and Taiwan.
Snapshot of Diabetes Prevalence (2009)Source: Frost & SullivanNon-insulin Therapeutics & Oral Based Insulin Injects New OpportunitiesThe diabetes therapeutics market has and will continue to experience growth, due to the rising need for non-insulin drugs with higher efficacy and easier modes of insulin administration.In 2009, the total revenue from China, India, South Korea, and Taiwan was approximately USD 2.5 billion. 60% of the total comprised of non-insulin therapeutics, while the insulin market made up the remaining 40%.China contributed to over half of the market size, with a revenue of USD 1.57 billion and is the only country who's insulin market size is larger than that of the non-insulin market.Chart above gives the total diabetes market size of the four countries.
Please click on the countries to expand.
Of the nearly 128 miillion indivduals in Japan, the diabetic population is estimated to be around 7.4 million. Nearly 83.0 per cent of this diabetic population has been diagnosed, with only 17.0 per cent remaining as undiagnosed for diabetes. This relatively high level of diagnosis offers easy market penetration for diabetes market participants. The hurdles of creating awareness among the population are restricted only to the rural areas where the 17.0 per cent of the undiagnosed population exist. A higher percent of aged population and the increasing incidence of diabetes are likely to be the major driving forces for the diabetes market in Japan.
China has overtaken India as the diabetes capital of the world, with an estimated 92 million affected in 2009, at a prevalence rate of 7.1%. Each year, there is an estimated 3 million new cases of diabetes (90% with Type II), with a suspected 150 million labeled pre-diabetic.
Such increments have been often linked to rapid economic growth, rising urban populations, dietary changes, and sedentary lifestyle. However, there are still 61% of diabetes cases that went undiagnosed in 2009, due to a combination of poor disease awareness and limited diagnostic centers.
The Chinese Ministry of Health (MOH) in partnership with Bayer, is working on an anti-diabetes campaign from 2010 to 2012 that will train doctors in diabetes management across 31 cities. China's MOH has also started programs to educate healthcare professionals and patients in rural areas about diabetes. In the past 5 years (2005-2009), about 3,000 to 5,000 doctors in 300 provinces received diabetes education.
According to the International Diabetes Federation, there were approximately 43 million Indians affected with diabetes in 2009. At a prevalence rate of 3.7% and 1.4 million new cases every year (90% with Type II), diabetes is slowly coming into public focus in India.
This trend has been linked to the increasing industrialization and urbanization of India, leading to sedentary lifestyles. Moreover, studies in India show that there is a higher 11% prevalence rate of diabetes in urban areas compared to the 3% in rural regions.
In 2009, the Indian government launched the pilot National Program for Prevention and Control of Diabetes, Cardiovascular Diseases and Stroke in 10 districts across 10 states. The program's objective was to test for diabetes in every Indian above the age of 35.
The state government of Gujarat was most active in educating postgraduate students of medicine in diabetes management through the Research Society for the Study of Diabetes in India (RSSDI). The RSSDI has also launched a project called Kadam to spread awareness among the residents of Ahmedabad and the rural areas adjacent to the city.
Diabetes is one of the fastest growing chronic diseases in South Korea, with the prevalence rate increasing five-fold over the past 30 years, from 1.5% to 7% in 2009. Each year diabetes increases by 120,000 new cases. Currently, there are 3.3 million diabetes cases in South Korea but by 2030, every 1 out of 7 South Koreans will be diabetic, at a 14% prevalence rate and will mostly be attributed to lifestyle factors such as changes in diet.
In 2009, the Ministry of Health & Family Welfare released a 5 Years Healthcare Roadmap targeted to launch in 2011, which indicated that the government would expand coverage of its medical insurance. The medical insurance coverage is expected to include reimbursement for self-diagnostic medical devices such as the Self-Monitoring Blood Glucose testing strips, which will encourage patient self-monitoring.
According to the National Health Research Institute, nearly 1 out 10 people in Taiwan suffered from diabetes in 2009. It is the 4th leading cause of death, after cancer, cerebrovascular, and heart disease. Nearly 2.2 million of Taiwanese were affected by diabetes and 200,000 new cases were reported every year. An increasing number of diabetics are under the age of 35, due to the combination of unhealthy diet, lack of exercise, and obesity.
The Taiwanese government has taken a financial approach to manage the rise in diabetes cases by offering healthcare insurance coverage for participating hospitals through the Bureau of National Health Insurance. It also provides financial incentives for healthcare providers to increase comprehensive follow-up visits.